Sulbactam/ampicillin in the treatment of acute pelvic inflammatory disease.
Acute pelvic inflammatory disease is associated with significant adverse reproductive sequelae. To prevent these serious sequelae, treatment regimens must cover the major etiologic agents which are Neisseria gonorrhoeae, Chlamydia trachomatis, and mixed anaerobic-aerobic bacteria. This report concerns the prospective evaluation of the efficacy of the combination of sulbactam with ampicillin in patients hospitalized with acute pelvic inflammatory disease. Clinical cure was noted in 33 (94%) of 35 patients and post-treatment cultures demonstrated eradication of N. gonorrhoeae and C. trachomatis in all cases.
Sweet
R L
RL
Department of Obstetrics and Gynecology, University of California, San Francisco.
Landers
D V
DV
Schachter
J
J
Crombleholme
W R
WR
D000328:Adult; D000667:Ampicillin / Q000009:adverse effects / Q000627:therapeutic use*; D001420:Bacteria, Aerobic / Q000187:drug effects; D001421:Bacteria, Anaerobic / Q000187:drug effects; D002440:Cefoxitin / Q000009:adverse effects / Q000627:therapeutic use; D004318:Doxycycline / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005839:Gentamicins / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008795:Metronidazole / Q000009:adverse effects / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy* / Q000382:microbiology; D011446:Prospective Studies; D013407:Sulbactam / Q000009:adverse effects / Q000627:therapeutic use*
D005839:Gentamicins; D008795:Metronidazole; D002440:Cefoxitin; D000667:Ampicillin; D004318:Doxycycline; D013407:Sulbactam